At a glance
ClinicalIndex Comparison RecordN/ACompleted· 20 enrolled
Drug / intervention
Rituxandrug
Likely dose
Rituxan 1000mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Cardiovascular Risk Markers in Patients With Rheumatoid Arthritis: Effect of Rituximab Therapy
In Brief
A clinical study evaluating Rituxan for Endothelial Function and 2 related conditions. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The purpose of this investigation is to determine the effects of Rituxan therapy in individuals with rheumatoid arthritis on endothelial function and other markers of endothelial function
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndothelial Function, Rheumatoid Arthritis, Inflammation
CountriesUnited States
CollaboratorsGenentech, Inc.
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2009
Enrollment StartNov 2009
Primary CompletionDec 2012
Study CompletionDec 2014
TodayJul 2026
First PostedFeb 16, 2009
Enrollment StartNov 1, 2009
Primary CompletionDec 1, 2012
Study CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 17.4 years ago
Interventions
Rituxandrug
1000mg rituxan by intravenous infusion will be given on day 1 and day 15 of the study